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validity of network meta-analysis; and (iv) the possibility of disagreement between 
direct evidence and indirect evidence. We illustrate the framework using a network 
meta-analysis of topical antibiotics without steroids for chronically discharging ears 
with underlying eardrum perforations.
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BAckground: In July 2013 the Department of Health referred terms of refer-
ence for value based assessment of health technologies to NICE. oBjective: We 
present the approach taken over the past 11 months to amending the Guide to 
Methods of Technology Appraisal to incorporate burden of illness and wider societal 
impact. Methods: Given the time frame available, NICE built on prior work under-
taken by the Department of Health (in the context of value based pricing) on the 
concepts of burden of illness and wider societal benefits by commissioning the NICE 
Decision Support Unit to review and critique this existing work. NICE reconvened the 
working party from the Guide to the Methods of Technology Appraisal review which 
took place in 2012, which included standing membership drawn from the stake-
holder communities such as patient and professional organisations, academia and 
pharmaceutical industry. The working party considered the prior work undertaken 
by the Department of Health and the Decision Support Unit’s critique for burden of 
illness and wider societal benefit, and provided advice on the incorporation of the 
2 new value elements into NICE’s current methods at 4 meetings. A consultation 
paper describing NICE’s proposals and draft of the amended sections of the methods 
guide was published in March 2014, and consultation ran for 12 weeks. It is antici-
pated that the final amendment of the methods guide will be considered by the 
NICE Board in advance of the ISPOR conference. results: Key points drawn from 
the discussion at the working party and consultation responses regarding burden 
of illness and wider societal impact, will be discussed. discussion: Considering 
NICE’s ‘position’ in the world of health technology assessment and appraisal, the 
conclusions from this latest amendment of the Guide to Methods of Technology 
Appraisal to incorporate value based assessment will be (highly) anticipated.
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oBjectives: To evaluate the cost-effectiveness (CE) of imaging-guided strategies 
for the diagnosis of significant coronary artery disease (CAD) in patients with inter-
mediate pre-test likelihood. Methods: Significant CAD was defined at invasive 
coronary angiography (ICA) as > 50% stenosis in the left main or > 70% stenosis in 
a major coronary vessel or 30-70% stenosis with fractional flow reserve ≤ 0.8.Nine 
diagnostic strategies were compared using a CE analysis. Strategies included the use 
of one single or two combined non-invasive imaging tests (CTCA as first line test 
and then stress ECHO, CMR, PET or SPECT) followed by ICA in the case of positivity 
of the single test or both non-invasive examinations in the case of combinations. 
ICERs were obtained using per-patient data collected throughout the EVINCI multi-
centre European study. Strategy costs were calculated using examination country-
specific reimbursements, while effectiveness was defined as the percentage of 
correct diagnosis. All costs were converted to Euro 2012 and adjusted using PPP. A 
propensity-score adjustment was used in the analysis and 95%CI were obtained 
with non-parametric bootstrap. results: Among the strategies analysed only three 
resulted cost-effective for the diagnosis of significant CAD. These included stress 
ECHO and CTCA as single non-invasive test, CTCA first then ECHO, CTCA first and 
then stress PET, all followed by ICA when required. Stress ECHO approach was the 
least costly but also the least effective, while CTCA alone [ICER: 2345 (2287-2400)] or 
in combination with PET [ICER: 5227(5161-5296)] had increasingly higher effective-
ness for a willingness to pay (WTP) exceeding 2,000 Euro and 5,000 Euro, respec-
tively. conclusions: Results from the health-economic analysis of the EVINCI 
study showed that stress ECHO guided diagnostic strategy could be cost-effective 
when the WTP is low. Strategies involving CTCA alone or as first line exam followed 
by stress PET could allow a more accurate diagnostic workflow for higher WTP.
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oBjectives: Clinical guideline recommendations are generally informed by pop-
ulation-based evidence. However, interventions that are (cost-)effective on average 
may not be (cost-)effective for many (even for most) patients meeting trial inclusion 
criteria. This study aims to investigate the value of risk-stratified recommendations 
for lung cancer screening among current or former smokers between the ages of 
55 and 74 years compared to a screen-all policy. Methods: Using data from the 
National Lung Cancer Screening Trial (NLST), we calculated the costs and QALYs 
for low-dose computed tomography (CT) versus chest radiography (X-ray) from 
empirically observed health states and 6 years life expectancy. Based on Kovalchik’s 
risk of lung cancer death prediction model, we stratified 53,454 NLST trial patients 
into quintiles. The expected value of individualized care (EVIC) was calculated to 
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oBjectives: To develop a set of criteria to critically appraise the strengths and 
weaknesses of health economic methods for the systematic valuation of interven-
tions for ultra-rare disorders (URDs). Methods: An international group of clinical 
and health economic experts met in conjunction with the Annual European ISPOR 
Congresses in Berlin/Germany and Dublin/Ireland, November 2012 and 2013, to 
deliberate and agree on a set of criteria to assess the potential of the various meth-
ods, which have been used or proposed to estimate the social value of medical 
interventions for URDs. results: The group identified a broad set of potential 
criteria, which may be grouped according to the following dimensions: theoreti-
cal foundations (normative premises, i.e., links to moral and economic theories, 
including - but not limited to – nonutilitarian consequentialist and deontological 
reasoning, definition and treatment of core concepts of economic thinking such 
as opportunity costs and efficiency), empirical underpinnings (social preferences 
related to attributes of the health condition or of the person afflicted with it), and 
pragmatic aspects (feasibility of implementation and potential for bias and misuse). 
For each of the dimensions, a set of criteria has been agreed upon, which in turn 
will need further scrutiny and justification. conclusions: Previously, a need had 
been identified for modifications or alternatives to the conventional logic of cost 
effectiveness applying benchmarks for the maximum allowable cost per quality-
adjusted life year (QALY). We propose a framework for the systematic assessment 
how well different evaluation approaches reflect prevalent social norms and value 
judgments. As a next step, the framework shall be applied on multi-criteria decision 
analysis methods and social cost value analysis, either using the person trade-off 
(PTO) or the relative social willingness-to-pay (RS-WTP) instrument.
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Rapid development of medical innovations in the face of rising health care costs have 
been calling for a more value-conscious adoption and diffusions of innovations. This 
conceptual paper departs from swift adoption of the da Vinci surgical robot in the 
Netherlands. It describes three challenges facing health care systems to evaluate 
promising, yet complex and often expensive medical innovations. Firstly, they are 
often adopted and diffused prior to their evidence-based superiority being proven. 
Secondly, formal evaluation frameworks are somehow detached from the dynamics 
of and incentives for adoption and diffusion of these innovations. Third, the real risks 
and benefits of these innovations are not easily amenable to an experimental inquiry. 
Unlike pharmaceuticals, whose impact is intrinsic to its biochemical components and 
thus can be subject to experiment, the value of complex surgical devices, imaging 
equipments, or targeted therapy interventions are inseparable from actual patterns 
of human practices and clinical pathways that utilize them. Multi-stakeholder (early) 
deliberation has often been proposed to better align value requirements with the 
adoption and diffusion processes. This article examines the importance of developing 
a shared value perspective on the implementation of complex innovations through 
early deliberation. Product developers, (potential) adopters (providers or patients), 
purchasers, and policy makers may engage in an upfront iterative deliberation on all 
the particularities and (pre)conditions that account for delivering value of a certain 
innovation during early adoption in a given care delivery setting. Such deliberation 
offers a cumulative learning as to how to reduce true-to-life uncertainties and risks 
‘along the way’, thereby serving for value ‘fulfillment’ in practice. Implication of such 
situated deliberative platforms for technology (outcome) assessment and for the role 
of authorities is discussed. A concrete framework for multi-stakeholder deliberation 
applied to the case of the da Vinci surgical robot in the Netherlands is also proposed.
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Systematic reviews that collate data about the relative effects of multiple inter-
ventions via network meta-analysis are highly informative for decision-making 
purposes. A network meta-analysis provides two types of findings for a specific 
outcome: the relative treatment effect for all pairwise comparisons, and a rank-
ing of the treatments. It is important to consider the confidence with which these 
two types of results can enable clinicians, policy makers and patients to make 
informed decisions. We propose an approach to determining confidence in the 
output of a network meta-analysis, based on methodology developed by the Grading 
of Recommendations Assessment, Development and Evaluation (GRADE) Working 
Group for pairwise meta-analyses. The suggested framework for evaluating a 
network meta-analysis acknowledges (i) the key role of indirect comparisons (ii) 
the contributions of each piece of direct evidence to the network meta-analysis 
estimates of effect size; (iii) the importance of the transitivity assumption to the 
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oBjectives: A binary reimbursement prediction model was previously developed 
based on a dataset of submissions to the Scottish Medicines Consortium (SMC) 
between 2006 and 2014. The objective of this study is to build on the previous model 
by identifying factors that influence the different levels of SMC recommendation, 
defined as “recommend”, “restrict” or “not recommend” pharmaceutical technolo-
gies for use in Scotland. Methods: Univariate and multivariate ordered logistic 
regression analyses were performed to assess the impact by means of odds ratios 
(OR) of the submitted evidence to the SMC on the decision. The proportional odds 
assumption underlying the current approach was tested. results: Out of 463 appli-
cations, 115 received positive recommendation (25%), 150 received restricted recom-
mendation (32%) and 198 (43%) were not recommended. Univariate analyses showed 
that 14 variables significantly affected the SMC decision. The multivariate analyses 
showed significant associations (p≤ 0.05) between the SMC decision and several 
variables, including: (1) a product demonstrating cost savings and QALY gains 
[OR= 6.11], (2) a product not being cost-effective (ICER≥ £30,000/QALY) [OR= 0.50], (3) 
a non-superior efficacy outcome versus placebo [OR= 0.15], (4) the product’s thera-
peutic indication (nervous system [OR= 0.51], blood forming organs [OR= 2.29]), (5) 
whether the product was indicated for non-chronic use [OR= 1.48] and (6) whether 
the submission was performed by a big company [OR= 1.86]. The proportional odds 
assumption was not violated, proving the appropriateness of the current model. The 
present model yielded similar results with the previously developed binary logistic 
one, further ensuring face validity, yet this approach is considered to better fit the 
multidimensional nature of SMC’s decision and increase the predictive power of 
the model. conclusions: This study identified superior efficacy using an active 
comparator as well as a beneficial cost-effectiveness outcome to increase the likeli-
hood of receiving a positive recommendation by the SMC.
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oBjectives: The entrenched positioning of biologics to treat moderate-to-severe 
rheumatoid arthritis (RA) has generated a lucrative market. However, amid ongo-
ing economic constraints, the EU5 (France, Germany, Italy, Spain, and the UK) must 
tighten their health care belts. As biosimilars versions of key brands appear on 
the horizon, this study explored the expected impact of these cheaper options 
on reimbursement and prescribing for RA in each country. Methods: Across the 
EU5, 254 rheumatologists were surveyed regarding their views on biosimilars for 
RA and on current and expected prescribing patterns. In addition, 15 payers who 
influence reimbursement at national or regional level were interviewed. results: 
Considering 54-week Phase III data, ≥ 80% of surveyed rheumatologists in each coun-
try believe CT-P13 (biosimilar infliximab) has similar efficacy to branded Remicade; 
however, respondents are less confident in the biosimilar’s safety. Furthermore, 
> 80% of respondents in most countries are willing to prescribe biosimilars of inf-
liximab, and of etanercept and rituximab, though largely not before branded biolog-
ics. Unsurprisingly, given likely price discounts, interviewed payers will somewhat 
encourage biosimilar uptake. However, excluding those in Germany, consensus is 
that discounts offered on biosimilars will not significantly impact their budgets. 
German payers, however, report that additional rebates to statutory insurers are 
expected; they admit to financial incentives for physicians to prescribe rebated 
drugs, thus manufacturers may consider robust uptake will compensate for hefty 
discounts. conclusions: Available data have inspired prescriber confidence in 
biosimilar efficacy, although safety concerns, likely stemming from complex bio-
similar manufacturing and lack of long-term safety data, will ensure continued 
brand uptake, at least initially. Furthermore, the expected modesty of biosimilar 
discounts in most countries will somewhat curb payer policy promoting use of such 
agents. However, as prescribers become more familiar with biosimilars, and, as the 
full extent of cost savings are revealed, increasing uptake of biosimilars is probable.
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oBjectives: Incentives are offered to pharmaceutical companies in order to 
increase the number of treatments for patients with rare diseases. As a conse-
quence, a number of new drugs have been introduced on the market—drugs that 
often fail to meet traditional cost-effectiveness criteria. This study aims to inves-
tigate if there are societal preferences for treating patients with rare diseases dif-
ferently in priority setting situations compared with common diseases. Moreover, 
psychological mechanisms that potentially could explain such preferences are 
explored. Methods: A postal questionnaire in three versions was sent out to a 
representative sample of the general Swedish population. Respondents were asked 
to choose to give treatment to a patient with a rare or a common disease in eight 
different scenarios. Rarity of the disease, different alternative costs, and group/
individual level decisions was investigated. Psychological aspects in the presented 
scenaros that varied between subjects was related to proportion dominance, the 
identifiability of the patient, pseudo-inefficacy and if the scenario was expressed in 
priority or rationing terms. results: Response rate was 41 % (n= 1239). For equal 
cost scenarios, 42.3 % were indifferent between the rare and the common group, 
23.9 % chose to prioritize the rare disease and 33.4 % the common disease. When 
questions were framed to be on an individul as opposed to a group level repond-
ents were significantly (p< .001) more likely to be indifferent. Proportion dominance 
increased individuals’ preferences to prioritize rare diseases (p< .001). Identifiability 
and pseudo-inefficacy had no major effect on respondents’ choices. conclusions: 
All else equal we see no strong support that a societal preference for rarity exists. 
However, we observe psychological effects influencing the judgments individuals 
make when setting priorities related to rare diseases. Whether or not these should 
quantify the value of using stratified information over population-based informa-
tion. results: The incremental cost-effectiveness ratio (ICER) of CT versus X-ray 
was $31,942 per QALY, for the “average” trial patient, indicating that CT would be 
the preferred option at a cost-effectiveness threshold of $50,000 per QALY. However, 
when stratified into quintiles, CT is dominated for the lowest risk quintile (i.e., X-ray 
is the preferred option for quintile 1) and CT is preferred for higher risk groups (quin-
tiles 2 to 5). The EVIC was calculated at around $180 per person for cost-effectiveness 
thresholds of $50,000 per QALY and higher. conclusions: Tailoring screening 
strategies to avoid CT scan in the lowest risk quintile of patients appears to be a 
superior strategy compared to population-wide CT scan screening, although results 
were sensitive to the cost-effectiveness threshold and the level of granularity of the 
analysis. This study shows the value of considering the risk-based heterogeneity 
of cost-effectiveness in clinical guideline recommendations and policy decisions.
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oBjectives: Self-monitoring of blood glucose (SMBG) may improve diabetes man-
agement. We analyzed the effect of SMBG on glycemic control, clinical outcomes 
and health care costs among insulin-users diabetic patients in a clinical practice 
setting. Methods: A retrospective analysis using data from the administrative 
databases, clinical registries containing laboratory results and medical devices data-
bases including SMBG strips data of two Italian Local Health Units was performed. 
Insulin-users were defined if they had at least one prescription of insulin agents from 
November, 2009 and April, 2011. The first prescription was selected as index-date. 
Patients were divided into two groups based on testing frequency of SMBG during 
the 18 months after the index-date: no test strip claims (no SMBG use) and more 
than two test strips per day. We calculated incidence rates to estimate the risk for 
fasting blood glucose levels < 70 mg/dl and for diabetes-related hospitalizations or 
death occurrence during the 18-months follow-up period. Total annual costs included 
hypoglycemic therapy and the direct costs due to diabetes-related hospitalizations 
and outpatient services. results: We identified 394 insulin-users patients with no 
SMBG use and 1350 with SMBG performed more than twice per day. Compared with 
non-SMBG use group, patients using SMBG showed a significant reduced risk of glu-
cose levels < 70 mg/dl (unadjusted rate was 10,6 vs 27,3 per 100 person-years, p< 0.001) 
and of diabetes-related hospitalizations or death (30,0 vs 60,8 per 100 person-years, 
p< 0.001). The higher hospitalization rate resulted in higher hospitalization costs per 
patient (€ 2.419 vs € 1.512 of those with SMBG use) and consequently higher total 
annual direct costs per patient (€ 3.060 vs € 2.738 of those using SMBG). conclusions: 
Results indicate that patients using SMBG, compared with non-SMBG patients, are 
associated with better glycemic control and reduced risk of diabetes-related hospi-
talizations and consequently with lower overall total annual cost per patient.
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oBjectives: Anxiety and mood disorders are highly prevalent in Primary Care but 
research shows that general practitioners (GPs) fail to diagnose up to half of cases. In 
this study we try to determine the diagnostic accuracy of GPs’ diagnoses of anxiety 
disorders with and without any help from diagnostic (assisted vs unassisted diagno-
sis). Methods: We searched for articles published from January 1980 to June 2014 in 
7 databases. We included studies in English, Spanish, French, and German reporting 
the ability of GPs to identify any anxiety disorder (DSM III/ IV/ IV-TR diagnostic crite-
ria) in Primary Care community samples. We excluded studies from general popula-
tion and those addressing specific physical or mental disorders, along with vignette 
and case-series studies. Two authors independently performed abstract and full-text 
reviews and data extraction. Study was assessed with the QUADAS-2. Coupled forest 
plots summarized estimated studies’ sensitivity and specificity and 95% confidence 
intervals. We fitted random-effects meta-analysis models and undertook a bivari-
ate meta-analysis to construct a summary Receiver Operator Characteristic Curve 
(sROC). results: From a total 17.964 detected papers, 443 were included for full text 
review. So far, we have analyzed 111 papers, out of which 8 studies were included 
with N= 3608 patients with pooled anxiety prevalence 26% (CI= 25-27%). Preliminary 
results shows an overall ROC curve with lower GP diagnostic accuracy when per-
forming unassisted diagnoses for a total diagnostic accuracy 80% (CI= 79.4-80.1) with 
overall sensitivity= 49% (CI= 45-53), and Specificity = 92% (CI= 90-94). GP’s accuracy 
was higher with assisted diagnoses (86.7%, CI= 85%-89%) than unassisted diagnoses 
(45.5%; CI= 43.7%-47.3%). Specificity was lower in assisted (89.15%; CI= 87.9-90.4) 
than unassisted diagnosis (92.5%; CI= 91.9-93.1). conclusions: Low diagnostic 
sensitivity might hinder the adequate detection and management of anxiety in 
primary care. Results suggest that detection might be improved by using diagnostic 
tools. Results for all included articles will be presented.
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